Oncolytics Biotech Inc. Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis NuCana plc (NASDAQ: NCNA) s

Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Oncolytics Biotech Inc. (NASDAQ: ONCY ) in January announced its partner in China — Adlai Nortye — has advanced the second dose level in a bridging clinical trial evaluating Oncolytics’ pelareorep in combination with paclitaxel therapy as a treatment for metastatic breast cancer. The news came after determination that the first dose level administered beginning in October showed no safety issues, and Oncolytics continues to complete parallel clinical trials of the same treatment in North America in collaboration with Pfizer Inc. (NYSE: PFE ) and Merck KGaA (OTCMKTS: MKKGY). The bridging trial will allow Adlai Nortye to include data from the North American metastatic breast cancer trials of the same combination treatment in future submissions to the National Medical Products Administration (NMPA), China’s regulatory equivalent of the Food and Drug Administration (FDA).

Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. In early December, Oncolytics Biotech Inc. (NASDAQ: ONCY ) presented the latest news on its Phase 2 study of the breast cancer treatment it’s developing at the 2021 San Antonio Breast Cancer Symposium . The biotech company has been working on its lead drug candidate, pelareorep, in partnership with a handful of industry leaders in the cancer therapy space. IRENE, a Phase 2 study investigating the use of Oncolytics’ pelareorep in combination with Incyte Corp. ’s (NASDAQ: INCY ) retifanlimab, was first announced in June 2020, and the initial doses were administered to patients in late August 2020. Now, Dr. Mridula George of Rutgers Cancer Institute of New Jersey has presented the latest safety data at the annual breast cancer symposium. Full story available on Benzinga.com

Oncolytics Biotech (ONCY) said no safety concerns were seen in the three-patient pancreatic cancer group of a phase 1/2 GOBLET study evaluating pelareorep in combination

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus LogicBio Phase 1/2 Study Of Genome Editing Therapy In Methylmalonic Acidemia Placed On Clinical Hold L

PALM BEACH, Fla. , Jan. 27, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018, breast cancer ranks as the fifth leading cause of deaths in women; accounting for 627,000 deaths every year. Moreover, as per estimates of the American Cancer Society, in U.S., 266,120 new cases were expected to be diagnosed in women by 2018. Furthermore, aging is considered as one of the greatest risk factors. According to Cancer Treatment Centers of America, women above 60 years of age are more likely to be diagnosed and only about 10% to 15% of cases occur in women younger than 45 years of age. High prevalence of the disease coupled with patent expiry are some of the major factors influencing investment in research and development of new products. The R&D spending from companies like Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Celgene Corporation; Pfizer, Inc.; GlaxoSmithKline plc; Sanofi; and AbbVie, Inc. has increased exponentially.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Atara To Sell Manufacturing Plant to Fuji's CDMO Unit For $100M Atara Biotherapeutics, Inc. (NASDAQ: A

Photo by Lucas Vasques on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Research and clinical trials have brought good news in treating pancreatic cancers in recent years, with the five-year survival rate increasing to 11%. However, the fight against many other cancers has advanced to a much higher survival rate. Metastatic pancreatic cancers, which spread from the primary site to other parts of the body through the bloodstream, are being investigated by several companies that are conducting clinical trials of new treatments to improve survival rates. In addition to studies being performed by large global companies such as Celgene Corp (XSWX: CELG), several biotech companies such as Paris-based Nanobiotix · (NASDAQ: NBTX ) and San Diego-based Oncolytics Biotech Inc. (NASDAQ: ONCY ) are reporting great strides in clinical trials. What is GOBLET? Oncolytics phase 1/2 trial, known as GOBLET ( G astrointestinal tum O rs exploring the treatment com B inations with the oncolytic reovirus pe L ar E orep and an T i-PD-L1) is a phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors.

Oncolytics Biotech <> provided enrollment update on a phase 1/2 GOBLET study of pelareorep in combination with Roche''s <> atezolizumab in patients with metastatic

Cheap penny stocks to watch right now. The post 4 Penny Stocks To Buy For Under $4 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Cheap penny stocks to watch right now. The post 4 Penny Stocks To Buy For Under $4 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Image provided by Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Cancer is the 2nd-leading cause of death in the United States, responsible for 1 in 4 deaths nationwide each year. With 3.8 million cases as of January 2021 and 250,000 new diagnoses each year, breast cancer is by far the most rapidly spreading type of cancer among women. Its also the 2nd most fatal, causing roughly 42,000 deaths per year. As cases continue to rise, the nations leading cancer researchers are working urgently to improve survival rates among breast cancer patients, especially those with later-stage metastatic breast cancer who have an abysmal 22% chance of surviving up to 5 years after diagnosis. Oncolytics Biotech Inc. (NASDAQ: ONCY ) hopes to change that with its lead drug candidate, pelareorep . With multiple clinical trials completed and underway, the biotechs immunotherapy drug candidate seems to offer the hope patients with metastatic breast cancer need, especially when combined with other leading treatments on the market today.

Oncolytics Biotech, Inc. (ONCY) shares closed today at 0.8% above its 52 week low of $1.30, giving the company a market cap of $72M. The stock is currently down 5.8% year-to-date, down 44.3% over the past 12 months, and up 297.0% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 0.1%. Trading Activity Trading volume this week was 35.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 1196.0% The company's stock price performance over the past 12 months lags the peer average by 676.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Wall Street analysts predict that Oncolytics Biotech Inc. (NASDAQ:ONCY) will post earnings of ($0.14) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Oncolytics Biotechs earnings. Oncolytics Biotech posted earnings of ($0.16) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 12.5%. []

Shares of Oncolytics Biotech Inc. (TSE:ONC) hit a new 52-week low during trading on Monday . The stock traded as low as C$1.85 and last traded at C$1.93, with a volume of 25835 shares trading hands. The stock had previously closed at C$1.94. The companys 50-day moving average is C$2.34 and its 200 day moving []